Today: 11 June 2026
Robinhood stock price edges up after-hours as MIAXdx deal sharpens prediction markets push
23 January 2026
1 min read

Robinhood stock price edges up after-hours as MIAXdx deal sharpens prediction markets push

NEW YORK, Jan 22, 2026, 19:29 EST — Trading after hours

  • Robinhood shares edged up 0.4% to $106.25 in after-hours trading.
  • MIAX announced it has sold 90% of MIAXdx to a joint venture between Robinhood and Susquehanna, retaining a 10% share.
  • Attention now turns to regulation of event contracts and Robinhood’s results set for Feb. 10.

Shares of Robinhood Markets Inc ticked up 0.4% to $106.25 in Thursday’s after-hours session.

The slight uptick follows investors digesting Robinhood’s latest move deeper into prediction markets, a segment more aligned with derivatives infrastructure than its main retail brokerage platform.

Having full or partial ownership of the rails is crucial. It influences the speed at which new products roll out, their approval timelines, and the share of profits retained within the group instead of flowing out to venues and middlemen.

Miami International Holdings, the operator behind MIAX, announced it has sold 90% of MIAX Derivatives Exchange (MIAXdx) to a joint venture formed by Robinhood and Susquehanna International Group. MIAX retains a 10% stake. MIAXdx operates under the U.S. Commodity Futures Trading Commission, offering fully collateralized futures, options on futures, and swaps—meaning customers must post the full value upfront rather than using leverage. MIAX CEO Thomas Gallagher said holding onto a portion allows the company to “gain exposure to the growing prediction market.” Robinhood’s JB Mackenzie added the acquisition “accelerates our investment in the prediction markets.” https://www.sec.gov/Archives/edgar/data/14…

A filing from MIAX confirmed the transaction took effect on Jan. 20.

The broader market edged higher on Thursday, led by gains in large-cap and tech-focused funds. Bitcoin, meanwhile, hovered mostly flat to a bit lower — a key dynamic for Robinhood since crypto trading often drives retail investor sentiment on its platform.

Robinhood isn’t the only player chasing fresh fee streams. Crypto-focused platforms like Coinbase, along with traditional brokers offering derivatives, have been ramping up their futures and options products, despite fluctuations in retail cash equity trading.

Prediction markets remain tangled in regulatory red tape. This week, a Massachusetts judge ruled that Kalshi cannot allow state residents to place sports bets on its platform without securing a license. The decision highlights the clash between state gaming laws and federally regulated event contracts.

Robinhood faces a ticking clock: when will the MIAXdx platform actually appear in the app as a tangible update? And how will the legal boundaries for sports-style contracts shift—will they expand or contract state by state?

Robinhood plans to release its fourth-quarter and full-year 2025 earnings on Feb. 10, after markets close.

Stock Market Today

  • AMD Stock Price Forecast: Analyst Lowers Target Amid AI Market Caution
    June 11, 2026, 11:00 AM EDT. Shares of Advanced Micro Devices (AMD) have surged 111% year-to-date, driven by investor optimism over its expanding role in the artificial intelligence (AI) sector. Despite the strong performance, a prominent AI-focused analyst has trimmed the price target for AMD, signaling caution about the chipmaker's near-term prospects. The analyst cited concerns over competitive pressures and potential market saturation. AMD's growth is largely tied to its ability to capture demand in AI computing, a fast-evolving field requiring specialized semiconductor technology. Investors are weighing the company's robust sales against risks from supply chain constraints and intensifying industry competition.

Latest articles

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

11 June 2026
TOVX soared 74.6% to $0.4252 after Theriva Biologics published Phase 1 VCN-01 data showing survival and biomarker signals in head-and-neck cancer, but the jump was not due to drug approval or revenue; investors face ongoing financing, dilution, and clinical-trial execution risks, with the company’s cash runway only into Q1 2027 and substantial doubt about its ability to continue as a going concern without new capital.
Trulieve Stock Turns Heads on NYSE After $50 Million Buyback

Trulieve Stock Turns Heads on NYSE After $50 Million Buyback

11 June 2026
Trulieve began NYSE trading as TRLV this week after moving from OTC/CSE, authorized a buyback of up to $50 million or 8.5 million shares, and closed its first NYSE session at $11.50, down 0.43%, before trading near $11.78 early Thursday, as investors weigh whether the uplisting and buyback will boost demand amid ongoing federal cannabis policy uncertainty.
Propanc Biopharma Jumps on $5 Million Buyback Plan, Investors React

Propanc Biopharma Jumps on $5 Million Buyback Plan, Investors React

11 June 2026
Propanc Biopharma shares soared as much as 392% after authorizing up to $5 million in stock buybacks—exceeding its prior $3.1 million equity value—even as it reported just $443,702 in cash and flagged going-concern risks, with investors now focused on whether its lead cancer drug PRP will advance to a planned Phase 1b trial this year.
Autodesk layoffs: AutoCAD maker to cut 1,000 jobs as it shifts spending to AI and cloud
Previous Story

Autodesk layoffs: AutoCAD maker to cut 1,000 jobs as it shifts spending to AI and cloud

AbbVie stock rises as Wall Street rallies; traders eye Feb. 4 earnings and the Fed next week
Next Story

AbbVie stock rises as Wall Street rallies; traders eye Feb. 4 earnings and the Fed next week

Go toTop